Fig. 4
From: Neuropilin-1 drives tumor-specific uptake of chlorotoxin
High NRP1 expression in PC-3 tumors correlates with ER-472 antitumor activity; anti-NRP1 blocking antibody treatment reduced ER-472 efficacy. a, expression of NRP1 mRNA in tumor lysates from 3 xenograft models. For each model n = 4 tumors, data represents mean ± SD. b, Western blot of NRP1 protein levels in tumor lysates, for each model at least 3 lysates were pooled for analysis (50 μg loaded onto gel) and data is representative of several individual experiments. Anti-NRP1 antibody detects both full length (~ 120 kDa) and soluble forms of protein (70–80 kDa); recombinant human NRP1 protein (15 ng) represents soluble/extracellular domain of NRP1. c, blocking anti-NRP1 antibody administered i.p. 30 min prior to ER-472 (0.9 mg/kg) diminished the PDC’s antitumor effect versus control IgG pre-treatment, *P ≤ 0.05 one-way ANOVA followed by Dunnett’s multiple comparison test